Login / Signup

Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma.

Sofia M SousaHelena BrancoAmir AvanAndreia PalmeiraLuca MorelliLúcio L SantosElisa GiovannettiMaria Helena VasconcelosCristina P R Xavier
Published in: Cancer chemotherapy and pharmacology (2024)
This work highlights the potential of darifenacin as a chemosensitizer for PDAC treatment.
Keyphrases
  • risk assessment
  • climate change
  • smoking cessation